REG - RUA Life Sciences - Notice of Results and Investor Presentation

Rua Life SciencesAnnouncement

07/07/2022 07:16

For best results when printing this announcement, please click on link below:
http://newsfile.refinitiv.com/getnewsfile/v1/story?guid=urn:newsml:reuters.com:20220707:nRSG5909Ra&default-theme=true

RNS Number : 5909R  RUA Life Sciences PLC  07 July 2022

7 July 2022

 

RUA Life Sciences Plc

 

("RUA Life Sciences", the "Company" or the "Group")

Notice of Results and Investor Presentation

RUA Life Sciences, the holding company of a group of medical device businesses
focused on the exploitation of the patented long-term implantable biostable
polymer, Elast-Eon(TM), announces the Group will release its audited annual
results for the year ended 31 March 2022 on 11 July 2022.

 

The Group will also conduct an investor presentation which will follow the
publication of the Group's final results.  The event will take place at
2.00pm on Monday 18 July with Bill Brown (Chairman) and Caroline Stretton
(Group Managing Director) presenting from the Company.

The online presentation is open to all existing and potential shareholders.
Questions can be submitted during the presentation to be addressed at the end.

To register for the event, please visit
www.equitydevelopment.co.uk/news-and-events/rua-life-sciences-fyresults-18july2022.

A recording of the presentation will be available shortly afterwards on the
Equity Developments website.

 

 

 

For further information contact:

 

RUA Life Sciences plc

Bill Brown,
Chairman
 
 
Tel: +44 (0) 77 3071 8296

Caroline Stretton, Group Managing Director
                                      Tel: +44 (0) 7789
901269

 

Cenkos Securities plc (Nominated Adviser and Broker)
                           Tel: +44 (0) 20 7397 8900

Giles Balleny/Max Gould (Corporate Finance)

Michael Johnson (Sales)

 

 

About RUA Life Sciences

The RUA Life Sciences group was created in April 2020 when RUA Life
Sciences Plc (formerly known as AorTech International Plc) acquired RUA
Medical Devices Limited to create a fully formed medical device business. RUA
Life Sciences is the holding company of the Group's four trading businesses,
each exploiting the Group's patented polymer technology.

Our vision is to improve the lives of millions of patients by improving and
enabling medical devices with Elast-Eon(TM), the world's leading long-term
implantable polyurethane.

Whether it is licensing Elast-Eon(TM), manufacturing a device or component or
developing next generation medical devices, a RUA Life Sciences business is
pursuing our vision.

 

Elast-Eon™'s biostability is comparable to silicone while exhibiting
excellent mechanical, blood contacting and flex-fatigue properties. These
polymers can be processed using conventional thermoplastic extrusion and
moulding techniques. With over 8 million implants and over 15 years of
successful clinical use, RUA's polymers are proven in long-term life enabling
applications.

 

The Group's four business units are:

 RUA Medical:           End-to-end contract developer and manufacturer of medical devices and
                        implantable fabric specialist.
 RUA Biomaterials:      Licensor of Elast-Eon(TM) polymers to the medical device industry.
 RUA Vascular:          Commercialisation of open surgical vascular grafts and patches

 RUA Structural Heart:  Development of polymeric leaflet systems for heart valves.

 

This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact
rns@lseg.com (mailto:rns@lseg.com)
 or visit
www.rns.com (http://www.rns.com/)
.

RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our
Privacy Policy (https://www.lseg.com/privacy-and-cookie-policy)
.   END  NORRFMFTMTJMBJT